Selexipag

Drug Profile

Selexipag

Alternative Names: ACT-293987; MRE-269; NS-304; Uptravi

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Antihypertensives; Pyrazines; Small molecules; Sulfonamides; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Arteriosclerosis obliterans; Pulmonary hypertension
  • Phase II Raynaud's disease

Most Recent Events

  • 08 Feb 2017 Phase-III clinical trials in Pulmonary hypertension in Japan (PO) (NipponShinyaku pipeline, February 2017)
  • 20 Oct 2016 Launched for Pulmonary arterial hypertension in Netherlands before October 2016 (PO)
  • 20 Oct 2016 Registered for Pulmonary arterial hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top